Voting has started for #ASH26 elections. We are rooting for Dr Wendy Stock running for Vice President! She is an incredible hematologist, researcher, mentor, sponsor and advocate. She has made enormous impact on so many lives and careers, including mine. So please vote!

Congratulations to Jommel Macaraeg for being selected by American Society of Hematology to receive the 2026 ASH Graduate Hematology Award, part of ASH’s investment in research and the next generation of hematologists! #ASHAwards  #Fight4Hematology Caner Saygin, MD https://ow.ly/ANRZ50Z6XMn

I was very inspired by the @abc7chicago.bsky.social @leukemiaresearch.bsky.social Gibbons 5K Run Event this morning! It was a blast to engage with our patients, families and friends to discuss leukemia research and raise money for this critical mission. abc7chicago.com/post/32nd-an...

How should we incorporate molecular data in treatment decisions for ALL? It is time to pay more attention to genetic heterogeneity of adult ALL before we decide therapy. Targeted therapies are rapidly emerging, and replacing chemo in ALL. Our review at Blood Cancer Discovery is out today! Link👇

We are very excited to share our work investigating menin inhibition in T-ALL, led by Kate Shimamoto and Arda Karaoglu, just published in Mol Cancer Therapeutics. We found that high p-MEF2C S222 can predict menin inhibitor response, better than HOX gene expression levels, in T-ALL. rb.gy/oroosm

very cool work led by @canersaygin.bsky.social lab looking at the potential for targeting menin in T-cell ALL! aacrjournals.org/mct/article/...

In a recent study, Caner Saygin, MD and team examined a large group of adults with a rare, aggressive form of leukemia called TP53-mutant ALL and found key genetic changes that guide doctors to predict which pts may face more serious outcomes. @uchicagomedicine.bsky.social https://ow.ly/cFsz50YgL2s

InO + TKI has robust activity but limited toxicity when drugs are given sequentially. Great option for older adults with Ph+ ALL in frontline.

Anand Patel@anand-88-patel.bsky.social · 9mo ago

Got to present our Ph+ ALL TKI plus inotuzumab study at #ASH25! Highlights: -all patients achieved MR4 or NGS negativity -VOD seen with initial schema, updated schema splitting InO and TKI had no VOD -80% OS and 76% EFS with no CNS relapse, one systemic relapse, and no allo-HCT

Our NCI study of HMA +/- Iadademstat is enrolling briskly for patients with HMA-naive accelerated/blast phase MPNs and overlap syndromes! www.cancer.gov/research/par...

In a new study, @canersaygin.bsky.social and colleagues show that TP53-mutant ALL is a high-risk, chemo-resistant subtype with poor survival, highlighting the need for tailored strategies. ow.ly/lvwo50WHJIr

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults - Blood Cancer Journal

Blood Cancer Journal - Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults

ow.ly

We’re thrilled to announce the 2025–2027 New Investigator Research Grant recipients—13 outstanding scientists from across the country who are pushing the boundaries of leukemia research. Meet the 2025–2027 awardees: bit.ly/474sfGP #LeukemiaResearch #ScientificDiscovery #FundingtheFuture

The Leukemia Research Foundation announces 2025-2027 research grant recipients

Northfield, IL - The Leukemia Research Foundation is pleased to announce the recipients of the 2025-2027 New Investigator Research Grant Program. Grants

bit.ly

Proud of our cancer program for being #1 in Illinois for the 3rd year in a row!! Learn more about our USNWR rankings at www.uchicagomedicine.org/forefront/ne...

U.S. News ranks University of Chicago Medical Center’s Cancer program best in state for third consecutive year - UChicago Medicine

The University of Chicago Medical Center earned national rankings in 10 adult specialties in the newly released U.S. News & World Report 2025-26 Best Hospitals list.

uchicagomedicine.org

Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN. Can we predict the risk for second blood cancer in myeloma pts? Grateful for the collaboration with @uchicagocancer.bsky.social myeloma program. www.nature.com/articles/s41...

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma - Leukemia

Leukemia - Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma

nature.com